Top of page

EPCORE™ NHL-2: A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma

A trial to find out whether epcoritamab, combined with chemotherapy, is safe and effective for people with different types of B-cell non-Hodgkin lymphoma.

This is a phase 1 (early phase) trial of an experimental treatment. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.


Trial aim and background

The aim of this trial is to find out whether the medication epcoritamab is safe in patients with B-cell lymphomas when combined with chemotherapy. Epcoritamab is a type of antibody called a ‘T-cell bispecific antibody’ (TCB) which attaches to two targets on different cells. It brings healthy T cells into close contact with cancerous B cells, boosting the immune response to the cancer. It is given as an injection under the skin.

Everybody in this trial has epcoritamab combined with chemotherapy. The chemotherapy regimen you have depends on your type of lymphoma.

You have your treatment in cycles. Each cycle is either 21 or 28 days, depending on the chemotherapy regimen you are having.


Who can enter

Adults with diffuse large B-cell lymphoma (DLBCL, double-hit or triple-hit lymphoma or follicular lymphoma may be eligible for this trial.


Locations

Recruitment is taking place in the following UK locations:

  • The Christie NHS Foundation Trust, Manchester
  • Freeman Hospital, Newcastle
  • Derriford Hospital, Plymouth

Further information

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at:  clinicaltrials.gov/ct2/show/NCT04663347

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.